Feroplus TR200 mg+200 mcg

Feroplus TR is indicated for:

• Established/guideline-supported use: Prevention and treatment of iron-deficiency anemia in pregnancy, when a combined iron and folic acid product is appropriate (routine antenatal iron and folic acid supplementation is recommended by WHO for pregnant women in areas/populations at risk of deficiency).
• Established/guideline-supported use: Prevention of folate-deficiency (megaloblastic) anemia of pregnancy, which can occur alongside iron-deficiency anemia due to increased maternal and fetal demand for both iron and folate.
• General use: Treatment of combined iron-deficiency and folate-deficiency anemia in non-pregnant adults and adolescents when both deficiencies are confirmed or strongly suspected.

Feroplus TR is not appropriate for anemias that are not due to iron and/or folate deficiency (e.g., anemia of chronic disease, hemolytic anemia, or vitamin B12-deficiency/pernicious anemia), and should not be used as a substitute for identifying and treating the underlying cause of anemia.

Ferrous Fumarate + Folic acid is a combination product containing:

• Ferrous Fumarate - an iron salt that provides elemental iron for hemoglobin synthesis.
• Folic acid - a synthetic form of vitamin B9 required for DNA synthesis and red blood cell maturation.

Strength and exact ratio of ferrous fumarate to folic acid vary by brand and formulation; refer to the specific product label for the elemental iron content (mg) and folic acid content (mg) per tablet/capsule.

Feroplus TR is a fixed-dose combination of an iron salt (ferrous fumarate) and folic acid, used mainly to prevent and treat iron-deficiency anemia and folate-deficiency (megaloblastic) anemia, particularly during pregnancy when the demand for both iron and folate rises substantially. Ferrous fumarate supplies elemental iron that is incorporated into hemoglobin, while folic acid supports the increased rate of red blood cell production that occurs in pregnancy and in recovery from anemia. Combining the two addresses two of the most common nutritional causes of anemia in pregnant women in a single product, which can improve adherence compared with taking separate supplements.

Feroplus TR belongs to the therapeutic class of Anti-anemic preparations, specifically Iron salts combined with folic acid (hematinics), used for the prophylaxis and treatment of iron-deficiency and folate-deficiency anemia.

Ferrous Fumarate + Folic acid combines two agents with complementary roles in erythropoiesis (red blood cell production):

• Ferrous fumarate is an iron(II) salt. After oral ingestion, iron is absorbed predominantly in the duodenum and proximal jejunum, where it is transported into enterocytes and then released into the circulation bound to transferrin. Transferrin delivers iron to the bone marrow, where it is incorporated into protoporphyrin to form heme, the oxygen-carrying component of hemoglobin. Adequate iron stores are essential for normal erythropoiesis; iron deficiency limits hemoglobin synthesis and produces microcytic, hypochromic anemia.
• Folic acid is a water-soluble B vitamin (vitamin B9). It is absorbed in the proximal small intestine and converted to its active metabolite, tetrahydrofolate, which is required for the synthesis of purines and pyrimidines (DNA precursors). Folate is essential for rapid cell division, including the maturation of red blood cell precursors in the bone marrow; deficiency results in ineffective erythropoiesis and megaloblastic anemia, characterized by large, immature red cells.

By supplying both iron and folate, Ferrous Fumarate + Folic acid supports normal hemoglobin synthesis and red cell maturation during periods of increased demand, such as pregnancy, when maternal iron and folate requirements rise substantially to support expansion of maternal red cell mass and fetal/placental growth.

Feroplus TR should be taken orally, preferably before meals for maximal iron absorption, though it may be taken with food if gastric irritation occurs. It should be swallowed whole with a full glass of water and taken at least 2 hours apart from tea, coffee, dairy products, calcium or antacid preparations, and tetracycline-class antibiotics to avoid reduced absorption of either agent.

Feroplus TR has the following well-documented, clinically significant interactions:

• Tetracycline antibiotics (e.g., tetracycline, doxycycline): Iron forms insoluble chelates with tetracyclines, substantially reducing absorption of both the antibiotic and the iron. Separate dosing by at least 2-3 hours (iron before or several hours after the tetracycline).
• Antacids (e.g., magnesium trisilicate, calcium/aluminum/magnesium-containing antacids): Reduce iron absorption by raising gastric pH and forming insoluble complexes. Take iron at least 2 hours apart from antacids.
• Tea, coffee, and calcium/dairy products: Tannins in tea/coffee and calcium in dairy/calcium supplements reduce iron absorption; avoid taking together with Feroplus TR.
• Penicillamine: Iron can reduce the absorption and therapeutic effect of penicillamine; separate administration is advised.
• Fluoroquinolone antibiotics (e.g., ciprofloxacin): Iron reduces absorption of fluoroquinolones through chelation; separate dosing is advised.
• Levodopa and levothyroxine: Iron may reduce absorption/efficacy of these drugs; separate dosing by several hours.
• Antiepileptic drugs (e.g., phenytoin): Folic acid can lower serum levels of some anticonvulsants, potentially reducing seizure control; monitoring is advised in patients on antiepileptic therapy.

Inform the prescribing physician of all other medications before starting Feroplus TR.

Side effects of Feroplus TR are mainly related to its iron component and are typically dose-related:

• Common (expected with iron therapy): Nausea, epigastric discomfort, constipation, diarrhea, and dark/black-colored stools (a harmless effect of unabsorbed iron).
• Less common: Vomiting, abdominal cramping, heartburn.
• Rare: Allergic-type reactions (rash, itching) related to folic acid or excipients.

Taking Feroplus TR with food (rather than on an empty stomach) can reduce gastrointestinal side effects, though this may slightly reduce iron absorption. Dark stools alone do not require stopping treatment, but new gastrointestinal bleeding should always be evaluated.

Pregnancy: Feroplus TR is commonly used during pregnancy specifically to prevent and treat iron-deficiency and folate-deficiency anemia, and routine iron and folic acid supplementation in pregnancy is supported by health authorities such as WHO. However, as with any medication in pregnancy, Feroplus TR should be used only under medical supervision, at doses appropriate for the trimester and degree of deficiency; high-dose iron supplementation is generally avoided in the first trimester unless clearly indicated. Consult a physician before use.

Lactation: Both iron and folic acid are considered compatible with breastfeeding at recommended doses, and supplementation is often continued postpartum. Use only as advised by a physician, and inform the doctor if breastfeeding.

The following precautions apply to Feroplus TR:

• Accidental pediatric ingestion: Iron-containing products, including Feroplus TR, can cause serious and potentially fatal toxicity if accidentally ingested by children in excessive amounts. Store Feroplus TR in a child-resistant container, out of sight and reach of children at all times, and seek emergency medical attention immediately if accidental ingestion by a child is suspected (see Overdose Effects).
• Masking of vitamin B12 deficiency: Folic acid can correct the megaloblastic anemia of vitamin B12 deficiency without correcting the associated neurological damage, which may progress unrecognized. B12 status should be assessed before or during folic acid therapy if B12 deficiency is suspected (e.g., in strict vegetarians/vegans, older adults, or those with malabsorption).
• Peptic ulcer disease or inflammatory bowel disease: Iron salts can aggravate gastrointestinal irritation; use with caution and medical supervision in patients with active peptic ulcer, ulcerative colitis, or other GI inflammatory conditions.
• Conditions of iron overload or abnormal iron utilization: Use with caution in patients with hemolytic anemias, hemochromatosis, or repeated blood transfusions, as iron accumulation can worsen these conditions.
• Persistent anemia: If anemia fails to respond to an adequate course of Feroplus TR, the diagnosis should be reviewed, as other causes of anemia may be present.

Overdose of Feroplus TR, particularly the iron component, is a medical emergency, especially in young children, in whom even a relatively small number of tablets can be fatal.

• Symptoms may include nausea, vomiting (sometimes bloody), abdominal pain, diarrhea, lethargy, and in severe cases, gastrointestinal bleeding, low blood pressure, metabolic acidosis, liver damage, and shock; symptoms can appear within hours and, after an apparent improvement, may be followed by delayed deterioration.
• Action: If overdose of Feroplus TR is suspected or witnessed, seek immediate emergency medical attention or contact a poison control center right away - do not wait for symptoms to appear. Take the product packaging with you to the hospital. Do not attempt home treatment or induce vomiting without professional medical guidance. Management in a medical facility may include supportive care and specific iron chelation therapy where indicated.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children, ideally in a child-resistant container.

Pregnant women: Feroplus TR is commonly used in pregnancy for prevention/treatment of iron and folate deficiency anemia under medical supervision (see Pregnancy and Lactation).

Pediatric population: Feroplus TR is generally not intended for use in young children; safety and efficacy of this specific fixed-dose combination in children have not been established, and dedicated pediatric iron/folic acid formulations with weight-based dosing should be used instead when a child requires supplementation. Accidental ingestion by children carries a serious risk of iron toxicity (see Precautions and Overdose Effects).

Elderly: No specific dose adjustment is generally required, but older adults should be assessed for underlying causes of anemia (including possible vitamin B12 deficiency or gastrointestinal blood loss) before and during use of Feroplus TR, and iron therapy should be used with care in those with a history of peptic ulcer or bowel disease.

Renal/hepatic impairment: No well-established specific dose adjustment is defined for Feroplus TR in renal or hepatic impairment; use with medical supervision in patients with significant hepatic disease, as iron overload can worsen liver injury.

Duration of Feroplus TR therapy depends on the indication: for prophylaxis in pregnancy, it is generally continued throughout pregnancy and often for a period postpartum (commonly around 3 months) as advised by the physician. For treatment of confirmed iron-deficiency anemia, therapy is typically continued for at least 3 months after hemoglobin normalizes to replenish body iron stores, with the total duration guided by clinical and laboratory response as determined by the treating physician.

Ferrous Fumarate + Folic acid belongs to the drug class of oral iron salts in combination with folic acid, within the broader category of hematinics/anti-anemic agents.

Ferrous Fumarate + Folic acid acts through two complementary mechanisms: the ferrous fumarate component provides elemental ferrous iron that is absorbed in the duodenum and upper jejunum and transported via transferrin to the bone marrow, where it is incorporated into heme for hemoglobin synthesis, correcting iron-deficiency anemia. The folic acid component is absorbed in the proximal small intestine and converted to tetrahydrofolate, a cofactor required for purine and pyrimidine (DNA) synthesis essential for the rapid cell division of maturing red blood cell precursors, thereby correcting or preventing folate-deficiency (megaloblastic) anemia.

Feroplus TR is not specifically formulated or dosed for pediatric use, and safety and efficacy of this fixed-dose adult combination have not been established in children. Iron and folic acid requirements in children with confirmed deficiency are usually met with dedicated pediatric preparations at weight-based doses under a physician's supervision, rather than with Feroplus TR. Because iron salts such as ferrous fumarate carry a serious risk of potentially fatal toxicity if ingested accidentally by a child, Feroplus TR must always be stored in a child-resistant container out of children's sight and reach, and any suspected accidental ingestion by a child requires immediate emergency medical attention.